Seminars in Nephrology
Volume 28, Issue 5 , Pages 493-498, September 2008

The Future of Pediatric Acute Kidney Injury Management—Biomarkers

  • Prasad Devarajan, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Prasad Devarajan, MD, Director of Nephrology and Hypertension, MLC 7022, 3333 Burnet Ave, Cincinnati, OH 45229-3039

Departments of Pediatrics and Developmental Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH

Summary 

Acute kidney injury (AKI) represents a common and devastating problem in clinical medicine. A major reason is the lack of early biomarkers for AKI, and hence an unacceptable delay in initiating therapy. Fortunately, the application of innovative technologies has uncovered several novel biomarkers. The most promising of these are included in a putative AKI biomarker panel, consisting of neutrophil gelatinase-associated lipocalin, interleukin-18, and kidney injury molecule-1. These biomarkers have completed initial validation, and have entered the prospective screening stage in the biomarker development process, facilitated by the development of commercial tools for their reproducible measurement across laboratories. The availability of a panel of validated biomarkers will revolutionize renal and critical care, and enable the practice of personalized and predictive medicine at an unprecedented level.

Keywords: Acute kidney injury, acute renal failure, biomarker, interleukin-18, kidney injury molecule-1, nephrotoxicity, neutrophil gelatinase-associated lipocalin, personalized medicine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Studies cited in this review that were performed in the author's laboratory were supported by grants from the National Institutes of Health (R01 DK53289, R01 DK069749, R01 HL08676, and R21 DK070163).

PII: S0270-9295(08)00118-6

doi:10.1016/j.semnephrol.2008.05.010

Seminars in Nephrology
Volume 28, Issue 5 , Pages 493-498, September 2008

Article Tools